The Global Ependymoma Drug Market is expected to reach US$407.21 million by 2034, up from US$218.25 million in 2025, registering a CAGR of 7.18% during the forecast period 2026–2034. Market growth is being supported by increasing focus on rare cancer treatment, advances in oncology research, growing investment in innovative therapeutics, and continued development...